Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
NCT03678883 · ACTIVE NOT RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Actuate Therapeutics Inc. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Actuate Therapeutics Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Actuate Therapeutics Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Actuate Therapeutics Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.